Blending single-cell biology with generative AI, Cellarity launches its first-in-human trial for CLTY-101—an engineered cell therapy targeting tumor …
Blending single-cell biology with generative AI, Cellarity launches its first-in-human trial for CLTY-101—an engineered cell therapy targeting tumor …
With a blockbuster IPO on the horizon, Australian biotech innovation is drawing global eyes and fresh capital to …
New partnerships and funding rounds are powering the rapid growth of RNA therapeutics.
New device approval and robust oncology funding highlight ongoing biopharma momentum in cancer therapies.
While VC investment cools, innovative startups find new ways to fuel biotech innovation and clinical progress.
With fresh capital and a new pipeline strategy, Replicor aims to tackle chronic viral infections and rare liver …
Already a subscriber? Log in